control limits around the mean calculated using the binomial distribution. The relationship between PDU size and outcome was also examined.
Results: Of the 169 PDUs included in the analysis, 42 (24.9%) lay outside the 95% control limits and 13 (7.7%) fell outside the 99.8% limits. The coefficient for the regression of the PDU size (per 100 patients) on the percentage of CYP with HbA1c <7.5% was 1.2 (95% CI from −0.6 to 3.1%, P=0.19).
Discussion: The percentage of CYP achieving the glycaemic target HbA1c <7.5% varied considerably across PDUs with one in four units exhibiting more variation than expected by chance. There was a nonsignificant trend for larger PDUs to achieve greater numbers reaching this performance indicator. Further work on individual-level data is needed to examine the extent to which the observed variation is warranted, i.e. due to differences in the sociodemographic and ethnicity profile of the populations served by different clinics, or unwarranted and potentially attributed to how local services organize and deliver diabetes care.
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